Edding Genor Group Holdings Company Description

Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally.

The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in clinical development for autoimmune diseases; and GB263T and GB268, tri-specific antibody candidates which are in preclinical and early clinical stages.

It also provides Vancocin for multidrug-resistant gram-positive bacteria; Ceclor for mild to moderate community-acquired bacterial infections in children; Yirui Ping for nebulized inhalation therapy; Vascepa for cardiovascular risk reduction; Mulpleta for reducing bleeding risk; Jing Zhu Da for breast cancer treatment; Recormon for CRA indication; and three siRNA candidates for chronic disease treatment, as well as entinostat and lerociclib hydrochloride tablets.

In addition, the company is involved in marketing, commercialization, and trading of pharmaceutical products; research and development of respiratory products; and consultancy and promotion services.

Its products are used in oncology, autoimmune, cardiovascular, respiratory, and anti-infective therapeutic areas.

The company was founded in 2001 and is headquartered in Zhuhai, China.